Search Results
Your search for The matches 34725 pages
Showing 17401 - 17450Prostate Cancer Foundation and Movember Foundation Announce 2018 Winners of Challenge Awards
The Prostate Cancer Foundation (PCF) and the Movember Foundation recently announced four new Movember Foundation–PCF Challenge Award teams at some of the world’s leading academic research institutions will receive a total of $3.5 million to support cross-disciplinary pioneering research toward the...
Every Day Is a Bonus
I have always been plagued with nagging headaches, so when they intensified in late 2010, I wasn’t too concerned. But when my eyes began involuntarily moving rapidly back and forth as I was writing Christmas cards, I knew the symptoms were a sign of something serious. A magnetic resonance imaging...
Outcomes After Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
In an interim analysis of a European trial reported in The Lancet Oncology, Francois-Xavier Mahon, MD, of Institut Bergonié, Bordeaux, and colleagues found that discontinuation of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (CML) with deep molecular response was...
PDL1 Amplification in Solid Tumors
In a study reported in JAMA Oncology, Aaron M. Goodman, MD, of the University of California, San Diego Moores Center for Personalized Cancer Therapy, and colleagues found amplification of PDL1 genes in 0.7% of solid tumors, including more than 100 tumor types. Response to checkpoint inhibition was ...
Treating Nonmetastatic Castration-Resistant Prostate Cancer: Implications of the PROSPER Trial
A MAN in his early 70s sits in our office. His general health is good, and he is feeling well. Yet he is deeply worried. Four years ago, when his prostate-specific antigen (PSA) level rapidly increased after radical prostatectomy and subsequent radiation therapy, he was started on...
Overall Survival Improved With Encorafenib/Binimetinib Combination in BRAF-Mutant Melanoma
IN PATIENTS with advanced BRAF V600–mutant melanoma, combining the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) improved overall survival compared to vemurafenib (Zelboraf) or encorafenib as monotherapy, with a favorable toxicity profile, according to updated...
If It Isn’t Documented, Does It Count?
“The quality of mercy is not strained. It droppeth as the gentle rain from heaven Upon the place beneath.” —William Shakespeare THESE LINES from The Merchant of Venice suggest that mercy should be freely given. However, the metrics of quality is strained, pouring like a thunderous storm obscuring...
Trametinib Treatment for Histiocytic Sarcoma With Activating MAP2K1 Mutation
In a letter to the editor in The New England Journal of Medicine, Mrinal M. Gounder, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues described the successful treatment of a patient with histiocytic sarcoma and an activating MAP2K1 (MEK1) mutation with the MAPK kinase 1 and...
Prediction of Survival and Disease Control in HPV-Negative Head and Neck Cancer Using Molecular Markers
A new method may predict the course of human papillomavirus (HPV)-negative head and neck cancer after radiochemotherapy. According to findings published by Hess et al in Clinical Cancer Research, five microRNAs (miRNAs) may be able to provide the decisive data. Squamous cell carcinomas of the head ...
A Story of a Mother and Daughter and Cancer
BOOKMARK Title: The Cookie Cure: A Mother-Daughter Memoir of Cookies and CancerAuthors: Susan Stachler With Laura StachlerPublisher: SourcebooksPublication date: February 2018Price: $19.95, paperback, 320 pages Cancer memoirs vary in their voice and message. Some are slapstick humorous attempts to ...
Erratum
In the July 10, 2018, issue of The ASCO Post, the article “KEYNOTE-407: Pembrolizumab Plus Chemotherapy Benefits Response, Survival in Squamous NSCLC” contained an error in the regimen for pembrolizumab (Keytruda). The study regimen, which has been corrected in the online version on ASCOPost.com,...
NCCN and CAOH Develop Guidelines to Improve Cancer Care in the Caribbean
The National Comprehensive Cancer Network® (NCCN®) is embarking on a new collaboration with the Caribbean Association for Oncology & Hematology (CAOH) to develop a library of NCCN Harmonized Guidelines™ for the Caribbean. The archipelago that extends from the Bahamas in the north to Trinidad...
FDA Grants Priority Review to sBLA for Pembrolizumab in Merkel Cell Carcinoma
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental biologics license application (sBLA) seeking accelerated approval for pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic...
Genetic Forecasting May Predict Response to Cetuximab in Colorectal Cancer
Blood tests could predict how long it takes until colorectal cancer becomes resistant to treatment based on the same principle used in forecasting the weather, a new study by Khan et al in Cancer Discovery has found. The liquid biopsies could also predict patients that are unlikely to initially...
Comparison of Methotrexate Intensification Regimens in Children and Young Adults With T-Cell ALL
As reported by Winter et al in the Journal of Clinical Oncology, findings in the Children’s Oncology Group (COG) AALL0434 trial indicate improved outcomes with a COG methotrexate intensification regimen vs a high-dose methotrexate intensification regimen in children and young adults with...
Rates of Inherited Breast Cancer in Nigerian Women
In a study reported in the Journal of Clinical Oncology, Zheng et al found a high frequency of inherited breast cancer among Nigerian women, with presence of deleterious mutations posing very high risk of disease. As noted by the investigators, “…Among Nigerian women, breast cancer is ...
Protein-Metabolite Panel for Detection of Early-Stage Pancreatic Cancer
In a study reported in the Journal of the National Cancer Institute, Fahrmann et al developed and validated a plasma-derived metabolite panel that distinguished early-stage pancreatic ductal adenocarcinoma (PDAC) with high accuracy. Accuracy was further improved with the addition of a previously...
Coriolus versicolor
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, present information on the potential...
Karen E. Knudsen, PhD, Named President-Elect of AACI Board of Directors
Karen E. Knudsen, PhD, Enterprise Director of the Sidney Kimmel Cancer Center (SKCC), Jefferson Health, has been elected Vice President/President-Elect of the Association of American Cancer Institutes’ (AACI) Board of Directors, a 2-year term that will begin September 30. Dr. Knudsen, who has...
Kristen Whitaker, MD, Joins Fox Chase Department of Clinical Genetics
Fox Chase Cancer Center has announced the hiring of Kristen Whitaker, MD, as Assistant Professor in the Department of Clinical Genetics. Dr. Whitaker treats patients with breast cancer and serves as a member of the clinical genetics team. Dr. Whitaker earned her medical degree from Drexel...
E. John Wherry, PhD, Named Chair of Systems Pharmacology at Perelman School of Medicine
E. John Wherry, PhD, has been appointed Chair of the Department of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine, University of Pennsylvania. Dr. Wherry is the Richard and Barbara Schiffrin President’s Distinguished Professor in the Department of...
Ronald D. Alvarez, MD, MBA, Elected to ABOG Board of Directors
Ronald D. Alvarez, MD, MBA, has been elected Director-At-Large of the Board of Directors for the American Board of Obstetrics and Gynecology (ABOG), a 6-year position he assumed on July 1. Until recently, he served as the ABOG Division Chair for the Gynecologic Oncology Subspecialty and the ABOG...
Ribociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 18, 2018, the indication for ribociclib (Kisqali) ...
Cheryl Lyn Walker, PhD, Receives NCI Outstanding Investigator Award
Cheryl Lyn Walker, PhD, Director of the Center for Precision Environmental Health and Professor in the Departments of Molecular and Cellular Biology, Medicine, and Molecular and Human Genetics at Baylor College of Medicine, has been awarded an Outstanding Investigator Award from the National...
NCCN Publishes New Guidelines for Rare Cancers Associated With Pregnancy
The National Comprehensive Cancer Network® (NCCN®) has released new treatment guidelines for a group of rare cancers that impact women during pregnancy. Gestational trophoblastic neoplasia, also known as gestational trophoblastic disease, may occur when tumors develop in the cells that would...
A Daughter Struggles Through Her Father’s Battle With Cancer
BOOKMARK Title: White Hot Grief Parade: A Memoir Author: Alexandra Silber Publisher: Pegasus Books Publication date: July 2018 Price: $25.95, hardcover; 288 pages The sudden death of a loved one produces a different type of trauma for family and friends than the protracted fading away of cancer. ...
Love in the Time of Cancer
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Ipilimumab in Combination With Nivolumab for MSI-H or dMMR Metastatic Colorectal Cancer
On July 10, 2018, ipilimumab (Yervoy) was granted accelerated approval for use in combination with nivolumab (Opdivo) for the treatment of patients at least 12 years of age with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer progressing...
Pediatric Surgeon Andrea Hayes-Jordan, MD, FACS, FAAP, Joins University of North Carolina
Andrea Hayes-Jordan, MD, FACS, FAAP, a pioneering surgeon and researcher, has been named Chief of the Division of Pediatric Surgery at the University of North Carolina (UNC) School of Medicine and Surgeon-in-Chief at the North Carolina Children’s Hospital. She officially joined the UNC School of...
First Large-Scale Survey of APPs in Oncology Shows Growing Role for Nurse Practitioners and Physician Assistants
Advanced practice providers (APPs) have increasingly become integral members of the oncology care delivery team, according to the first large-scale study of nurse practitioners (NPs) and physician assistants (PAs) in oncology. The study was conducted collaboratively by ASCO, the American Academy of ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Barbados
GUEST EDITOR The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. Each installment focuses on a country from one of the six regions of the world, as defined by the World Health Organization (ie, Africa, the Americas, South-East Asia, Europe, Eastern...
Improving the Lives of Patients With Cancer Is Richard L. Schilsky’s Lifelong Mission
In 2009, as Richard L. Schilsky, MD, FACP, FSCT, FASCO, was preparing his Presidential Address for that year’s ASCO Annual Meeting, he came across his 6th grade essay titled “My Ambition,” which foretold with eerie specificity the career path he would follow over the next 6 decades. In the paper,...
Active Surveillance of Lung Subsolid Nodules May Reduce Unnecessary Surgery and Overtreatment
Subsolid nodules can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance. Conservative management of subsolid nodules may reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from...
Bringing Together Industry, Academia, and Nonprofits to Advance Breast Cancer Research
In 2016, the Breast Cancer Research Foundation (BCRF) launched the Drug Research Collaborative, a program the foundation developed to bridge the gap between academic investigators and their access to therapies under investigation and to encourage greater academia-driven research in breast cancer....
FDA Accepts sBLA for Dasatinib in Pediatric Patients With Newly Diagnosed Ph-Positive ALL
The U.S. Food and Drug Administration (FDA) recently accepted a supplemental biologics license application (sBLA) for dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia...
Study Examines Link Between Squamous Cell Carcinoma and Recessive Dystrophic Epidermolysis Bullosa
Many patients with the rare skin disease recessive dystrophic epidermolysis bullosa (RDEB)—commonly called butterfly syndrome—also develop squamous cell carcinoma early in life. Now an international team of scientists led by researchers at the Sidney Kimmel Cancer...
Patient-Reported Financial Sacrifice and Cancer Care
In a study reported in the Journal of Oncology Practice, Chino et al found that high proportions of insured patients with cancer—most with stage IV disease—reported being willing to make considerable personal and financial sacrifices to receive cancer care. The study included a...
Brentuximab Vedotin Plus Gemcitabine in Pediatric and Young Adult Patients With Relapsed/Refractory Hodgkin Lymphoma
In a Children’s Oncology Group phase I/II trial reported in The Lancet Oncology, Cole et al found that the combination of brentuximab vedotin (Adcetris) and gemcitabine was active in pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma. As noted by the...
CNS Activity of First-Line Osimertinib in EGFR-Mutant Advanced NSCLC
In a subgroup analysis of the phase III FLAURA trial reported in the Journal of Clinical Oncology, Reungwetwattana et al found evidence of greater central nervous system (CNS) activity of osimertinib (Tagrisso) vs standard EGFR tyrosine kinase inhibitors in patients with previously untreated...
Sequential Liquid Biopsy Sampling May Be a Predictive Tool for Early Disease Progression in Patients With Colorectal Cancer
According to the American Cancer Society, excluding skin cancers, colorectal cancer is the third most common cancer among men and women in the United States, with over 97,000 new cases expected this year, and is the third leading cause of cancer-related death, with over 50,000 deaths predicted in...
Statement From FDA Commissioner on Support for Exempting Coffee From California’s Cancer Warning Law
Scott Gottlieb, MD, Commissioner of the U.S. Food and Drug Administration, recently issued the following statement: “Ensuring that food is safe and truthfully labeled is one of our fundamental responsibilities at the FDA. Consumers deserve accurate information about the food they eat and how ...
Sex-Based Approaches to Oncology in the Era of Precision Oncology: Upcoming ESMO Workshop
Sex-based approaches to studying and treating disease have remained largely unexplored in medical oncology, despite the field’s growing interest in precision medicine and accumulating evidence that sex is a major factor in disease risk and response to treatment. At an upcoming European...
Radiomic Signature for CD8 Cell Tumor Infiltration and Response to Treatment
In a study reported in The Lancet Oncology, Sun et al developed a radiomic signature of infiltrating CD8 cells that could identify tumor immune phenotype and help predict outcome of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor treatment. Study Details...
Near-Infrared Fluorescence With Indocyanine Green Dye vs Isosulfan Blue Dye for Detecting Sentinel Nodes in Gynecologic Cancers
In the phase III FILM study reported in The Lancet Oncology, Frumovitz et al found that near-infrared fluorescence imaging with indocyanine green dye identified more sentinel nodes vs isosulfan blue dye in women with clinical stage I endometrial or cervical cancer undergoing curative surgery. There ...
Cancer May Be Linked to Poor Prognosis in Patients With Broken Heart Syndrome
Cancer may be linked to an increased risk of death and prehospitalization in patients with broken heart syndrome, according to research presented by Santoro et al at the 2018 European Society of Cardiology Congress. Study author Francesco Santoro, MD, of the University of Foggia, Italy, said, ...
Nonalcoholic Fatty Liver Disease May Be Risk Factor for Liver Cancer
Nonalcoholic fatty liver disease is a common disease, and with the incidence of liver cancer rising across the country, little has been understood about the link between it and hepatocellular carcinoma. To establish a better understanding of the link between hepatocellular carcinoma risk and...
Tumor Mutation Burden and Prognosis in Resected NSCLC
In a study reported in the Journal of Clinical Oncology, Devarakonda et al found that high nonsynonymous tumor mutation burden was associated with improved outcomes in patients undergoing resection for non–small cell lung cancer (NSCLC). Study Details The study (Lung Adjuvant Cisplatin...
Adding First-Line Pertuzumab to Trastuzumab Plus Aromatase Inhibitor in Advanced Breast Cancer
In the phase II PERTAIN trial reported in the Journal of Clinical Oncology, Rimawi et al found that adding pertuzumab to trastuzumab plus an aromatase inhibitor improved progression-free survival in patients with advanced HER2-positive, hormone receptor–positive breast cancer. Study Details ...
Immunotherapy Combination in Melanoma Brain Metastases
In the phase II CheckMate 204 study reported in The New England Journal of Medicine, Tawbi et al found that combined nivolumab (Opdivo) and ipilimumab (Yervoy) produced a high rate of intracranial clinical benefit in patients with melanoma brain metastases. Study Details The study included 94...
Quality Improvement Initiative for Documenting Goals of Care for Patients With Advanced Cancer
In a study reported in the Journal of Oncology Practice, Karim et al found that a quality improvement initiative at a single cancer center improved documentation of goals-of-care discussions and referral to palliative care for patients with advanced cancer. Study Details In the study,...
